The response of MAX-associated somatotroph tumours to somatostatin receptor ligands has been less convincing and multimodal therapies have been required (Roszko et al. 2017, Daly et al. 2018, Kobza et al. 2018, Seabrook et al. 2021). The gene discussed is MAX; the disease is neoplasm.